Postmortem Metabolomics of Insulin Intoxications and the Potential Application to Find Hypoglycemia-Related Deaths

Postmortem metabolomics can assist death investigations by characterizing metabolic fingerprints differentiating causes of death. Hypoglycemia-related deaths, including insulin intoxications, are difficult to identify and, thus, presumably underdiagnosed. This investigation aims to differentiate insulin intoxication deaths by metabolomics, and identify a metabolic fingerprint to screen for unknown hypoglycemia-related deaths. Ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry data were obtained from 19 insulin intoxications (hypo), 19 diabetic comas (hyper), and 38 hangings (control). Screening for potentially unknown hypoglycemia-related deaths was performed using 776 random postmortem cases. Data were processed using XCMS and SIMCA. Multivariate modeling revealed group separations between hypo, hyper, and control groups. A metabolic fingerprint for the hypo group was identified, and analyses revealed significant decreases in 12 acylcarnitines, including nine hydroxylated-acylcarnitines. Screening of random postmortem cases identified 46 cases (5.9%) as potentially hypoglycemia-related, including six with unknown causes of death. Autopsy report review revealed plausible hypoglycemia-cause for five unknown cases. Additionally, two diabetic cases were found, with a metformin intoxication and a suspicious but unverified insulin intoxication, respectively. Further studies are required to expand on the potential of postmortem metabolomics as a tool in hypoglycemia-related death investigations, and the future application of screening for potential insulin intoxications.

[1]  C. Aguilar-Salinas,et al.  Metabolomic markers of glucose regulation after a lifestyle intervention in prediabetes , 2022, BMJ Open Diabetes Research & Care.

[2]  F. Farzadfar,et al.  Metabolic signatures of insulin resistance in non-diabetic individuals , 2022, BMC Endocrine Disorders.

[3]  D. Wishart,et al.  Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials , 2022, Pharmacological Reviews.

[4]  F. Farzadfar,et al.  Targeted metabolomics analysis of amino acids and acylcarnitines as risk markers for diabetes by LC–MS/MS technique , 2022, Scientific Reports.

[5]  R. Zoja,et al.  Postmortem forensic toxicology cases: A retrospective review from Milan, Italy , 2022, Journal of forensic sciences.

[6]  H. Gréen,et al.  Postmortem Metabolomics Reveal Acylcarnitines as Potential Biomarkers for Fatal Oxycodone-Related Intoxication , 2022, Metabolites.

[7]  E. d’Aloja,et al.  Infant urinary metabolomic profile in a fatal acute methadone intoxication , 2022, International Journal of Legal Medicine.

[8]  H. Gréen,et al.  The Importance of BHB Testing on the Post-Mortem Diagnosis of Ketoacidosis , 2021, Biomolecules.

[9]  E. d’Aloja,et al.  Looking for Post-Mortem Metabolomic Standardization: Waiting for Godot-The Importance of Post-Mortem Interval in Forensic Metabolomics. , 2021, Chemical research in toxicology.

[10]  E. d’Aloja,et al.  Metabolomics improves the histopathological diagnosis of asphyxial deaths: an animal proof-of-concept model , 2021, Scientific Reports.

[11]  H. Gréen,et al.  Post-Mortem Metabolomics: A Novel Approach in Clinical Biomarker Discovery and a Potential Tool in Death Investigations. , 2021, Chemical research in toxicology.

[12]  A. Krętowski,et al.  Applications of Metabolomics in Forensic Toxicology and Forensic Medicine , 2021, International journal of molecular sciences.

[13]  M. Bohnert,et al.  Metabolomics in postmortem cerebrospinal fluid diagnostics: a state-of-the-art method to interpret central nervous system–related pathological processes , 2020, International Journal of Legal Medicine.

[14]  D. Wescott,et al.  Postmortomics: The Potential of Untargeted Metabolomics to Highlight Markers for Time Since Death , 2020, Omics : a journal of integrative biology.

[15]  E. Tai,et al.  Serum acylcarnitines and amino acids and risk of type 2 diabetes in a multiethnic Asian population , 2020, BMJ open diabetes research & care.

[16]  T. Zeller,et al.  Long-Chain Acylcarnitines and Cardiac Excitation-Contraction Coupling: Links to Arrhythmias , 2020, Frontiers in Physiology.

[17]  V. P. Novoselov,et al.  Post-mortem changes in metabolomic profiles of human serum, aqueous humor and vitreous humor , 2020, Metabolomics.

[18]  T. Kraemer,et al.  Postmortem metabolomics: Correlating time-dependent concentration changes of xenobiotic and endogenous compounds. , 2020, Drug testing and analysis.

[19]  Xilin Yang,et al.  The Association Between Acylcarnitine Metabolites and Cardiovascular Disease in Chinese Patients With Type 2 Diabetes Mellitus , 2020, Frontiers in Endocrinology.

[20]  L. Fanton,et al.  Is insulin intoxication still the perfect crime? Analysis and interpretation of postmortem insulin: review and perspectives in forensic toxicology , 2020, Critical reviews in toxicology.

[21]  O. Melander,et al.  Purine Metabolites and Carnitine Biosynthesis Intermediates Are Biomarkers for Incident Type 2 Diabetes , 2019, The Journal of clinical endocrinology and metabolism.

[22]  Ruonan Wang,et al.  Profile of cardiac lipid metabolism in STZ-induced diabetic mice , 2018, Lipids in Health and Disease.

[23]  E. Ingelsson,et al.  Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance , 2018, Scientific Reports.

[24]  E. Liepinsh,et al.  Plasma acylcarnitine concentrations reflect the acylcarnitine profile in cardiac tissues , 2017, Scientific Reports.

[25]  E. Liepinsh,et al.  Acute and long‐term administration of palmitoylcarnitine induces muscle‐specific insulin resistance in mice , 2017, BioFactors.

[26]  N. Secher,et al.  Liver and Muscle Contribute Differently to the Plasma Acylcarnitine Pool During Fasting and Exercise in Humans. , 2016, The Journal of clinical endocrinology and metabolism.

[27]  Dolores Corella,et al.  Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions. , 2016, The American journal of clinical nutrition.

[28]  C. Aguilar-Salinas,et al.  Metabolomics in diabetes, a review , 2016, Annals of medicine.

[29]  N. Sunderland,et al.  Fatal Insulin Overdoses: Case Report and Update on Testing Methodology , 2016, Journal of forensic sciences.

[30]  R. McPherson,et al.  Acylcarnitines: potential implications for skeletal muscle insulin resistance , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  S. Toennes,et al.  Factors leading to the degradation/loss of insulin in postmortem blood samples. , 2014, Forensic science international.

[32]  E. Liepinsh,et al.  Long-chain acylcarnitine content determines the pattern of energy metabolism in cardiac mitochondria , 2014, Molecular and Cellular Biochemistry.

[33]  Hui Sun,et al.  Metabolomics in diabetes. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[34]  M. Copetti,et al.  Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. , 2014, Atherosclerosis.

[35]  M. Graber The incidence of diagnostic error in medicine , 2013, BMJ quality & safety.

[36]  L. Ström,et al.  Liquid chromatography/time-of-flight mass spectrometry analysis of postmortem blood samples for targeted toxicological screening , 2013, Analytical and Bioanalytical Chemistry.

[37]  F. Vaz,et al.  Acylcarnitines: reflecting or inflicting insulin resistance? , 2013, Diabetes.

[38]  Nele Friedrich,et al.  Metabolomics in diabetes research. , 2012, The Journal of endocrinology.

[39]  R. Wanders,et al.  Characterization of D-3-hydroxybutyrylcarnitine (ketocarnitine): an identified ketosis-induced metabolite. , 2012, Metabolism: clinical and experimental.

[40]  F. Toledo,et al.  Increased Levels of Plasma Acylcarnitines in Obesity and Type 2 Diabetes and Identification of a Marker of Glucolipotoxicity , 2010, Obesity.

[41]  C. Hoppel,et al.  Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. , 2009, The Journal of nutrition.

[42]  H Druid,et al.  Postmortem identification of hyperglycemia. , 2009, Forensic science international.

[43]  Ken-ichi Yoshida,et al.  Biochemical blood markers and sampling sites in forensic autopsy. , 2008, Journal of forensic and legal medicine.

[44]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[45]  Nigel W. Hardy,et al.  Proposed minimum reporting standards for chemical analysis , 2007, Metabolomics.

[46]  O. Fiehn Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.